Trial Profile
A Randomized Phase II Study of MCS110 Combined With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Dec 2021
Price :
$35
*
At a glance
- Drugs Lacnotuzumab (Primary) ; Carboplatin; Gemcitabine
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Novartis; Novartis Pharma A.G.; Novartis Pharmaceuticals
- 06 Oct 2021 a protocol amendment after the enrollment halt where survival follow-up was removed, biomarker sample collections were no longer required and the frequency of post Cycle 8 assessments was reduced from every 9 weeks to a minimum of every 12 weeks until disease progression, and at the end-of-treatment visit, as per results published in the Clinical Cancer Research
- 06 Oct 2021 Primary endpoint (Progression Free Survival (PFS) as Per RECIST v1.1 (by Local Investigator Assessment)) has not been met as per results published in the Clinical Cancer Research
- 06 Oct 2021 Results published in the Clinical Cancer Research